Key Products

Genomic Profiling

They offer worldwide access to our comprehensive genomic profiling services and data-driven solutions to help inform patient care and advance precision oncology decisions.

Clinical Trial Matching

The TIME Trial Program is a just-in-time network of providers to support rapid patient identification, site activation, and enrollment of select clinical trials. Through the TIME Trial Program, 1,500 oncologists and their patients have access to a large portfolio of cutting-edge precision medicine trials.

Companion Diagnostics

Tempus offers a data-driven approach to companion diagnostic development across our portfolio of assays, leveraging a broad-panel platform used by thousands of oncologists. These assays, including a 648 targeted gene panel, whole transcriptome (RNA), and liquid biopsy, can each incorporate multiple companion diagnostic biomarkers.

Multi Omics

High throughput solutions provide comprehensive datasets for consumer, academic, and research needs. They offer a broad range of technologies to support your high throughput needs, from genotyping to methylation to NGS.

Key Executives

Eric Lefkofsky, Founder & CEO

Eric Lefkofsky is the founder and CEO at Tempus, a leading provider of technology enabled precision medicine solutions. He is a founding partner of Lightbank, a venture fund investing in disruptive technology businesses. He is also the co-founder and Chairman of Groupon (NASDAQ: GRPN), a global e-commerce marketplace, and co-founder of Mediaocean, a leading provider of integrated media procurement technology; Echo Global Logistics (NASDAQ: ECHO), a technology-enabled transportation and logistics outsourcing firm; InnerWorkings (NASDAQ: INWK). He co-chairs the Lefkofsky Family Foundation with his wife Liz to advance high-impact initiatives that enhance lives in the communities served. Lefkofsky serves as a Trustee of Lurie Children’s Hospital of Chicago, The Art Institute of Chicago, The Museum of Science and Industry, and World Business Chicago. He is also Chairman of the Board of Trustees of Chicago’s Steppenwolf Theatre Company. Lefkofsky is an adjunct professor at the University of Chicago and author of Accelerated Disruption: Understanding the True Speed of Innovation. He graduated from the University of Michigan and received his Juris Doctor at University of Michigan Law School.

Shane Colley, Chief Technology Officer

Shane Colley is the Chief Technology Officer at Tempus. Prior to joining Tempus, Colley was Vice President of Research and Development at R1 RCM (formerly Accretive Health), where he built and led a global organization of over 200 product, architecture, design, and development professionals that were responsible for R1’s technology portfolio. Colley earned his Bachelor of Science in Computer Science from Iowa State University.

Ryan Fukushima, Chief Operating Officer

Ryan Fukushima serves as Chief Operating Officer at Tempus. Prior to Tempus, Fukushima was an Entrepreneur-in-Residence and Vice President at Lightbank, focusing investments on enterprise software and launching businesses. Earlier he was at Hyde Park Venture Partners, where he concentrated on enterprise investments in the Midwest. Before landing in Chicago, Fukushima worked predominantly as an engineer, designing and implementing backend systems for Cisco and VMware. Fukushima has received a bachelor’s degree in Engineering from California Polytechnic University and holds an MBA from the Ross School of Business at University of Michigan, where he was a Zell Scholar.

Stacey Kraft, Chief People Officer

Stacey is Tempus’ Chief People Officer, responsible for leading the People Operations team, driving a culture that inspires and motivates the entire team to deliver on our mission of improving patient outcomes. Prior to joining Tempus, Stacey was the Chief People Officer at Enova International, a leading FinTech company in Chicago. Stacey’s 20 years of HR leadership experience has been tested and validated in fast-paced, high-growth technology and professional services industries in private and public companies and non-profit institutions such as Groupon, Enova, Thomson Reuters, and the Museum of Science & Industry. She holds a BA in Geography from Indiana University and is an inspired breast cancer survivor.

Erik Phelps, EVP and Chief Administrative and Legal Officer

Erik Phelps serves as Executive Vice President and Chief Administrative and Legal Officer at Tempus. He oversees various functions within the company, including legal, quality, compliance, corporate risk, and external affairs in addition to working closely with communications and human resources. Prior to joining Tempus, he was the General Counsel at Epic, a software company that provides electronic health records for medical groups, hospitals and healthcare organizations. Prior to his time there, he served as a partner at Michael Best & Friedrich LLP in Madison, WI where he focused on software licensing and technology-related work, including work with early-stage companies. He earned a bachelor’s degree from Beloit College and his J.D. from George Washington University Law School.

Jim Rogers, Chief Financial Officer

Jim Rogers serves as Chief Financial Officer at Tempus, where he is responsible for overseeing the Company’s Accounting, FP&A, Treasury, and Investor Relations’ functions. Prior to joining Tempus, Jim held various finance positions at Groupon, including leading FP&A for the North America business and serving as the financial controller of Asia Pacific operations. Prior to Groupon, Jim was part of Ernst & Young’s assurance practice, where he worked with various financial services firms. Jim earned his B.B.A. in Accounting from the University of Notre Dame and his MS in Accounting from Northern Illinois University.

Customer insights

“In the rapidly changing world of cancer care and precision medicine, Tempus is the established leader. They provide rapid, accurate results while also continuing to develop innovative strategies to improve patient outcomes. With a focus on both clearly defining actionable mutations and extending treatment options by matching specific patients to specific local and national studies, Tempus is directly changing the patients’ lives.” – Joseph K Hofmeister, Md, Ohiohealth

“Breast cancer care has involved use of biomarkers for years in order to determine appropriate therapy. Genomic information has now been added to the list of crucial biomarkers needed to know how to treat metastatic breast cancer patients with the approval of targeted therapy for BRCA and PIK3CA mutations. Having this information also gives a patient the best opportunity to consider one of numerous biomarker driven clinical trials. These options allow as personalized an approach to treatment as possible and I have no doubt that genomic data will continue to transform the way patients are treated as our field moves forward.” – Megan Kruse, MD, Cleveland Clinic

Company insights

“We are thrilled to have led an investment in Tempus… Given NEA’s long and successful history investing in the intersection of technology and life science, we felt like the perfect strategic partner given Tempus’ mission to help doctors personalize care by collecting and analyzing large volumes of data.” – Peter Barris, Chairman & General Partner, New Enterprise Associates

“I look forward to working with the Tempus team as they continue to apply technology and artificial intelligence to healthcare, deploying intelligent diagnostics that enhance research, empower physicians, and positively change the lives of patients.” – Jennifer Doudna, PhD, Li Ka Shing Chancellor’s Professor of Biomedical Science, University of California, Berkeley

“As a surgical oncologist, I have worked to reduce racial, ethnic and gender health care disparities throughout my career. Tempus is a leader in the field of data-driven medicine, and I am excited to work with their team to further enhance patient outcomes for individuals of all backgrounds and from all communities.” – Wayne A. I. Frederick, MD, MBA, Charles R. Drew Professor of Surgery

“I’m honored to be working with the Tempus team as they advance innovative tools for personalizing patient care and empower providers with information that can help them make better and more informed treatment decisions for their patients.” – Scott Gottlieb, MD, Scientific Advisor

“Having spent my entire career at the forefront of emerging technologies, it’s exciting to see how healthcare is finally embracing the very technologies that have transformed so many other industries. This is a space that is near and dear to me, and I’m excited to be a part of Tempus as they seek to bring big data, artificial intelligence and advanced molecular analysis to those suffering with cancer and other life threatening diseases.” – Ted Leonsis, Cofounder & Partner, Revolution Growth

“It is an honor to serve with the Tempus team — professionals with a passion to transform healthcare through technology that facilitates patients rapidly getting the best treatment available for their unique situations; to relieve their suffering, improve their health and save their lives.” – Nadja West, LTG (ret), MD, 44th U.S. Army Surgeon General